196 related articles for article (PubMed ID: 21265638)
1. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
[TBL] [Abstract][Full Text] [Related]
2. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
4. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
Geyer LB; Menna Barreto SS; Weigert LL; Teixeira AR
Braz J Otorhinolaryngol; 2015; 81(6):589-97. PubMed ID: 26480907
[TBL] [Abstract][Full Text] [Related]
5. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
7. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.
Garinis AC; Keefe DH; Hunter LL; Fitzpatrick DF; Putterman DB; McMillan GP; Gold JA; Feeney MP
Ear Hear; 2018; 39(1):69-84. PubMed ID: 28708814
[TBL] [Abstract][Full Text] [Related]
8. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
[TBL] [Abstract][Full Text] [Related]
9. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.
Stavroulaki P; Vossinakis IC; Dinopoulou D; Doudounakis S; Adamopoulos G; Apostolopoulos N
Arch Otolaryngol Head Neck Surg; 2002 Feb; 128(2):150-5. PubMed ID: 11843723
[TBL] [Abstract][Full Text] [Related]
10. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
11. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss in cystic fibrosis.
Martins LM; Camargos PA; Becker HM; Becker CG; GuimarĂ£es RE
Int J Pediatr Otorhinolaryngol; 2010 May; 74(5):469-73. PubMed ID: 20189661
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
McRorie TI; Bosso J; Randolph L
Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
[TBL] [Abstract][Full Text] [Related]
14. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.
Gleser MA; Zettner EM
Int J Audiol; 2018 Dec; 57(12):917-924. PubMed ID: 30382794
[TBL] [Abstract][Full Text] [Related]
15. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review.
Farzal Z; Kou YF; St John R; Shah GB; Mitchell RB
Laryngoscope; 2016 Jan; 126(1):228-35. PubMed ID: 26152803
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.
Handelsman JA; Nasr SZ; Pitts C; King WM
Pediatr Pulmonol; 2017 Sep; 52(9):1157-1162. PubMed ID: 28737283
[TBL] [Abstract][Full Text] [Related]
17. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD.
Tokgoz B; Somdas MA; Ucar C; Kocyigit I; Unal A; Sipahioglu MH; Oymak O; Utas C
Ren Fail; 2010 Jan; 32(2):179-84. PubMed ID: 20199179
[TBL] [Abstract][Full Text] [Related]
18. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS
J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.
O'Donnell EP; Scarsi KK; Scheetz MH; Postelnick MJ; Cullina J; Jain M
Int J Antimicrob Agents; 2010 Jul; 36(1):94-5. PubMed ID: 20382508
[No Abstract] [Full Text] [Related]
20. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.
Appana D; Joseph L; Paken J
S Afr J Commun Disord; 2016 Nov; 63(1):e1-e12. PubMed ID: 28155306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]